Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Open Access
- 28 September 2019
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (3), 1-8
- https://doi.org/10.14218/jcth.2019.00033
Abstract
Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus (HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This is the first phase 2/3 study conducted in Mainland China confirming the efficacy and safety of RDV + ritonavir-boosted danoprevir + ribavirin for 12 weeks in treatment-naïve noncirrhotic patients with genotype 1 infection in a large population.Keywords
This publication has 12 references indexed in Scilit:
- Twelve‐week ravidasvir plus ritonavir‐boosted danoprevir and ribavirin for non‐cirrhotic HCV genotype 1 patients: A phase 2 studyJournal of Gastroenterology and Hepatology, 2018
- Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutionsWorld Journal of Hepatology, 2017
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2016
- Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b PatientsPLOS ONE, 2016
- Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionJournal of Gastroenterology and Hepatology, 2013
- How to optimize HCV therapy in genotype 1 patients: predictors of responseLiver International, 2013
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesJournal of Hepatology, 2011
- Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative BehaviorBiochemistry, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateJournal of Hepatology, 2008
- Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)Antimicrobial Agents and Chemotherapy, 2008